As demonstrated by the different efficacy of BRAF inhibitors in melanoma and colon cancer [17], the inclusion of multiple tumor types with the same molecular target in a basket trial might introduce an important source of heterogeneity and could lead to negative results. This evidence concerns the gene BRAF and colonic neoplasm.